Time to Reconsider AxoGen, Inc. (AXGN) After Making 52-Week High?

June 21, 2018 - By Hazel Jackson

AxoGen, Inc. (NASDAQ:AXGN) Logo

The stock of AxoGen, Inc. (NASDAQ:AXGN) hit a new 52-week high and has $54.75 target or 6.00 % above today’s $51.65 share price. The 5 months bullish chart indicates low risk for the $1.97 billion company. The 1-year high was reported on Jun, 21 by Barchart.com. If the $54.75 price target is reached, the company will be worth $118.20M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 1.62% or $0.85 during the last trading session, reaching $51.65. About 160,679 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 194.48% since June 21, 2017 and is uptrending. It has outperformed by 181.91% the S&P500.

Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on August, 1. They expect $-0.08 EPS, down 33.33 % or $0.02 from last year’s $-0.06 per share. After $-0.11 actual EPS reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 4 analysts covering AxoGen (NASDAQ:AXGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen has $45 highest and $34 lowest target. $42’s average target is -18.68% below currents $51.65 stock price. AxoGen had 7 analyst reports since January 8, 2018 according to SRatingsIntel. The firm has “Market Outperform” rating given on Thursday, March 1 by JMP Securities. The firm earned “Market Outperform” rating on Tuesday, May 1 by JMP Securities. Lake Street maintained the stock with “Buy” rating in Friday, March 2 report. Cantor Fitzgerald maintained AxoGen, Inc. (NASDAQ:AXGN) on Wednesday, February 28 with “Buy” rating. As per Tuesday, May 1, the company rating was maintained by Cantor Fitzgerald. Cantor Fitzgerald maintained the shares of AXGN in report on Monday, January 8 with “Buy” rating.

More recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Globenewswire.com which released: “Report: Developing Opportunities within Wix, AxoGen, YPF Sociedad Anonima, Orix Corp Ads, Travelport Worldwide …” on June 04, 2018. Also Nasdaq.com published the news titled: “AxoGen, Inc. Announces Repayment in Full of its $25 million Outstanding Debt” on May 29, 2018. Globenewswire.com‘s news article titled: “AxoGen, Inc. to Present at Upcoming Investor Conferences” with publication date: June 06, 2018 was also an interesting one.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.97 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: